EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Next-generation multiplex-edited CAR-NK cells: more edits, more power?

Tobias Bexte, Dimitrios L Wagner

Journal for ImmunoTherapy of Cancer · 2025-09 · 13 (9) · e012841

DOI: 10.1136/jitc-2025-012841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 15.09.2025. Verfasst von Tobias Bexte und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Experimental Immunology and Celltherapy, Goethe University Frankfurt, Frankfurt am Main, Germany bexte@med.uni-frankfurt.de. Hauptthemen laut MEDLINE: Killer Cells, Natural, Gene Editing, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

First clinical trials demonstrated the safety of adoptive cell transfer with allogeneic natural killer (NK) cell products from healthy donors, making them an attractive candidate for ‘off-the-shelf’ chimeric antigen receptor (CAR)-immune cell therapy. However, reduced persistence and inactivation of NK cells by immunosuppressive cues likely limit the performance of CAR-redirected NK cells. Wang and colleagues demonstrate that multiplex CRISPR base editing allows optimization of the intrinsic functionality of CAR-NK cells improving their therapeutic potential. In contrast to conventional CRISPR-Cas nucleases, base editing avoided most double-stranded DNA breaks while enabling highly efficient editing at up to six sites simultaneously. The study further demonstrates the feasibility of a non-viral approach to integrate CAR transgene and multiplex base editing of several immune checkpoints in NK cells using a single electroporation. CAR-NK cells harboring up to three base edits demonstrate improved potency over unedited counterparts in vitro. Xenograft mouse models confirmed increased potency, but also indicated signs of organ toxicity - a phenomenon that will require future studies prior to clinical translation. The study demonstrates that CRISPR base editing is a powerful tool to unleash the full cytotoxic potential of NK cells, but it also warrants the question: How many internal breaks can be removed without hurting CAR-NK cell therapy’s impeccable safety record?

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalGene EditingReceptors, Chimeric AntigenImmunotherapy, AdoptiveHumansAnimalsMiceCRISPR-Cas Systems

Stichwörter der Autor:innen

Adoptive cell therapy - ACTChimeric antigen receptor - CARImmune Checkpoint InhibitorImmunotherapyNatural killer - NK

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Pediatrics, Experimental Immunology and Celltherapy, Goethe University Frankfurt, Frankfurt am Main, Germany bexte@med.uni-frankfurt.de.
  • Institute for Transfusion Medicine and Immunohematology, German Red Cross Hesse, Frankfurt am Main, HE, Germany.
  • Berlin Center for Advanced Therapies, Charité - Universitätsmedizin Berlin, Berlin, BE, Germany.
  • Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
  • Berlin Institute of Health Center for Regenerative Therapies, Berlin Institute of Health at Charité, Berlin, BE, Germany.

Zitieren

APA

Bexte, T., & Wagner, D. L. (2025). Next-generation multiplex-edited CAR-NK cells: more edits, more power?. Journal for ImmunoTherapy of Cancer, 13(9), e012841. https://doi.org/10.1136/jitc-2025-012841

Vancouver

Bexte T, Wagner DL. Next-generation multiplex-edited CAR-NK cells: more edits, more power?. Journal for ImmunoTherapy of Cancer. 2025;13(9):e012841. doi:10.1136/jitc-2025-012841

BibTeX
@article{Bexte2025,
  author = {Bexte, Tobias and Wagner, Dimitrios L},
  title = {Next-generation multiplex-edited CAR-NK cells: more edits, more power?},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {9},
  pages = {e012841},
  doi = {10.1136/jitc-2025-012841}
}
Kostenlos starten →